WO2019051122A3 - CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS - Google Patents

CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS Download PDF

Info

Publication number
WO2019051122A3
WO2019051122A3 PCT/US2018/049798 US2018049798W WO2019051122A3 WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3 US 2018049798 W US2018049798 W US 2018049798W WO 2019051122 A3 WO2019051122 A3 WO 2019051122A3
Authority
WO
WIPO (PCT)
Prior art keywords
regions
activated binding
conditionally activated
binding moieties
moieties containing
Prior art date
Application number
PCT/US2018/049798
Other languages
French (fr)
Other versions
WO2019051122A2 (en
Inventor
Robert B. Dubridge
Anand PANCHAL
Original Assignee
Maverick Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics, Inc. filed Critical Maverick Therapeutics, Inc.
Priority to CN201880072457.XA priority Critical patent/CN111315773A/en
Priority to JP2020513722A priority patent/JP2020534811A/en
Priority to EP18782834.8A priority patent/EP3679068A2/en
Publication of WO2019051122A2 publication Critical patent/WO2019051122A2/en
Publication of WO2019051122A3 publication Critical patent/WO2019051122A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Provided herein are compositions of conditionally activated binding proteins containing Fc regions, and methods for coexpressing and purifying such conditionally activated binding proteins. Also provided are methods of treating cancer by administering the conditionally activated binding proteins to a patient.
PCT/US2018/049798 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS WO2019051122A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201880072457.XA CN111315773A (en) 2017-09-08 2018-09-06 Conditionally active binding moieties comprising an Fc region
JP2020513722A JP2020534811A (en) 2017-09-08 2018-09-06 Conditionally activated binding moiety containing the Fc region
EP18782834.8A EP3679068A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762555943P 2017-09-08 2017-09-08
US201762555999P 2017-09-08 2017-09-08
US62/555,943 2017-09-08
US62/555,999 2017-09-08

Publications (2)

Publication Number Publication Date
WO2019051122A2 WO2019051122A2 (en) 2019-03-14
WO2019051122A3 true WO2019051122A3 (en) 2019-04-11

Family

ID=63788012

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/049798 WO2019051122A2 (en) 2017-09-08 2018-09-06 CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS

Country Status (4)

Country Link
EP (1) EP3679068A2 (en)
JP (1) JP2020534811A (en)
CN (1) CN111315773A (en)
WO (1) WO2019051122A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL302614A (en) 2017-09-08 2023-07-01 Maverick Therapeutics Inc Constrained conditionally activated binding proteins
EP3833444A1 (en) 2018-08-09 2021-06-16 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
US11685780B2 (en) 2019-03-05 2023-06-27 Takeda Pharmaceutical Company Limited Single domain antigen binding domains that bind human Trop2
US20220144949A1 (en) 2019-03-05 2022-05-12 Takeda Pharmaceutical Limited Company CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS
SG11202112541RA (en) * 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
JP2023540533A (en) * 2020-09-04 2023-09-25 武田薬品工業株式会社 Constrained and conditionally activated binding protein constructs with human serum albumin domains
EP4334354A1 (en) 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
CA3238936A1 (en) 2021-11-24 2023-06-01 Wayne A. Marasco Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP3534749B2 (en) 1991-08-20 2004-06-07 アメリカ合衆国 Adenovirus-mediated gene transfer into the gastrointestinal tract
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
CA2166118C (en) 1993-06-24 2007-04-17 Frank L. Graham Adenovirus vectors for gene therapy
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
PT1222292E (en) 1999-10-04 2005-11-30 Medicago Inc METHOD FOR REGULATING THE TRANSCRIPTION OF EXOGENEOUS GENES IN THE PRESENCE OF NITROGEN
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE10231109A1 (en) 2002-07-10 2004-01-22 Daimlerchrysler Ag exhaust turbine
CA2908988A1 (en) * 2013-04-19 2014-10-23 Covagen Ag Novel bispecific binding molecules with antitumoral activity
CN106632681B (en) * 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 Anti- EGFR and AntiCD3 McAb bispecific antibody and its application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2010081173A2 (en) * 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
WO2016046778A2 (en) * 2014-09-25 2016-03-31 Amgen Inc Protease-activatable bispecific proteins
WO2016179285A1 (en) * 2015-05-04 2016-11-10 Cytomx Therapeutics, Inc. Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2016187594A1 (en) * 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2017156178A1 (en) * 2016-03-08 2017-09-14 Maverick Therapeutics, Inc. Inducible binding proteins and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAD MAY ET AL: "Advances in bispecific biotherapeutics for the treatment of cancer", BIOCHEMICAL PHARMACOLOGY, vol. 84, no. 9, 1 November 2012 (2012-11-01), pages 1105 - 1112, XP055071310, ISSN: 0006-2952, DOI: 10.1016/j.bcp.2012.07.011 *
FRANKEL STANLEY R ET AL: "Targeting T cells to tumor cells using bispecific antibodies", ENGINEERED PROTEIN SCAFFOLDS AS NEXT-GENERATION ANTIBODY THERAPEUTICS,, vol. 17, no. 3, 1 June 2013 (2013-06-01), pages 385 - 392, XP002787546, ISSN: 1879-0402 *

Also Published As

Publication number Publication date
JP2020534811A (en) 2020-12-03
CN111315773A (en) 2020-06-19
WO2019051122A2 (en) 2019-03-14
EP3679068A2 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
WO2019051122A3 (en) CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS
MX2020013881A (en) Bcl-xl inhibitory compounds and antibody drug conjugates including the same.
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
ZA201906269B (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2019009468A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
MX2017007641A (en) Antibody drug conjugates with cell permeable bcl-xl inhibitors.
AU2016293674B2 (en) A novel approach for treatment of cancer using immunomodulation
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
SG10201900315SA (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
SG10201908388UA (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP4233910A3 (en) Methods of treatment of cholestatic diseases
MX2019009566A (en) Proteins binding bcma, nkg2d and cd16.
CR20200334A (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EP4011871A3 (en) Processes for preparing oxathiazin-like compounds
WO2014151369A3 (en) Stabilized ezh2 peptides
MX2018015172A (en) Methods of treating pancreatic cancer.
EP4342473A3 (en) Compounds useful in hiv therapy
MX2019009943A (en) Proteins binding gd2, nkg2d and cd16.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
AU2018321118A1 (en) Boronic acid derivatives
MX2017010341A (en) Cancer therapy with a parvovirus combined with bevacizumab.
MX2019009847A (en) Proteins binding cd123, nkg2d and cd16.
MX2022014792A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18782834

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2020513722

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018782834

Country of ref document: EP

Effective date: 20200408